A Study to Evaluate ENERGI-F705 Tablets in Healthy Volunteers (NCT07650383) | Clinical Trial Compass
CompletedPhase 1
A Study to Evaluate ENERGI-F705 Tablets in Healthy Volunteers
Taiwan24 participantsStarted 2025-02-24
Plain-language summary
To evaluate the safety, the tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of ENERGI-F705 Tablets in healthy subjects.
Who can participate
Age range
18 Years – 45 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. All genders aged ≧18 to \< 45 years.
. Able to understand and sign informed consent form.
. Able to communicate well with the Investigator and comply with the requirements of the study.
. Body mass index (BMI) ranged 18.5≦BMI \< 27 kg/m2 .
. Males weighting ≧50 kg and females weighting ≧45 kg.
. Healthy subjects as determined by a responsible physician, based on medical evaluation including medical history, physical examination, concomitant medication, vital signs, 12-lead ECG, chest X-ray, and clinical laboratory evaluations.
. Is willing to follow the study life style instruction and protocol procedure
. Negative test for human immunodeficiency virus (HIV), syphilis, hepatitis B virus surface antigen (HBsAg), and anti-HCV antibody at screening.
Exclusion criteria
. History of adverse reactions or allergy of active ingredient, components in IP or related products.
. Significant drug abuse.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number and Percentage of Subjects with Treatment-Emergent Adverse Events (TEAEs)
Timeframe: From dosing through end of study (approximately 4 days post-dose)
. Having any medical history as judged by the Investigator (including but not limited to neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorders).
. Presence of significant neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, renal, or other pathology, as judged by the Investigator.
. Pregnant or lactating women.
. Having an acute illness or surgery within 4 weeks prior to dosing.
. Other conditions not suitable for participating in this study as judged by the Investigator.
. History of cancer (malignancy) or have ever received any anti-cancer therapy.